Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 16

1.

Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial.

DuBois SG, Marachelian A, Fox E, Kudgus RA, Reid JM, Groshen S, Malvar J, Bagatell R, Wagner L, Maris JM, Hawkins R, Courtier J, Lai H, Goodarzian F, Shimada H, Czarnecki S, Tsao-Wei D, Matthay KK, Mosse YP.

J Clin Oncol. 2016 Apr 20;34(12):1368-75. doi: 10.1200/JCO.2015.65.4889. Epub 2016 Feb 16.

2.

Molecular profiling of childhood cancer: Biomarkers and novel therapies.

Saletta F, Wadham C, Ziegler DS, Marshall GM, Haber M, McCowage G, Norris MD, Byrne JA.

BBA Clin. 2014 Jun 28;1:59-77. doi: 10.1016/j.bbacli.2014.06.003. eCollection 2014 Jun. Review.

3.

Fifteen years of irinotecan therapy for pediatric sarcoma: where to next?

Wagner LM.

Clin Sarcoma Res. 2015 Aug 28;5:20. doi: 10.1186/s13569-015-0035-x. eCollection 2015. Review.

4.

Usefulness of 18F-Fluorodeoxyglucose Positron Emission Tomography for Follow-Up of 13-cis-Retinoic Acid Treatment for Residual Neuroblastoma After Myeloablative Chemotherapy.

Sato Y, Kurosawa H, Sakamoto S, Kuwashima S, Hashimoto T, Okamoto K, Tsuchioka T, Fukushima K, Arisaka O.

Medicine (Baltimore). 2015 Aug;94(31):e1290. doi: 10.1097/MD.0000000000001290.

5.

Nanoparticle delivery of an SN38 conjugate is more effective than irinotecan in a mouse model of neuroblastoma.

Iyer R, Croucher JL, Chorny M, Mangino JL, Alferiev IS, Levy RJ, Kolla V, Brodeur GM.

Cancer Lett. 2015 May 1;360(2):205-12. doi: 10.1016/j.canlet.2015.02.011. Epub 2015 Feb 12.

6.

Targeting the DNA repair pathway in Ewing sarcoma.

Stewart E, Goshorn R, Bradley C, Griffiths LM, Benavente C, Twarog NR, Miller GM, Caufield W, Freeman BB 3rd, Bahrami A, Pappo A, Wu J, Loh A, Karlström Å, Calabrese C, Gordon B, Tsurkan L, Hatfield MJ, Potter PM, Snyder SE, Thiagarajan S, Shirinifard A, Sablauer A, Shelat AA, Dyer MA.

Cell Rep. 2014 Nov 6;9(3):829-41. doi: 10.1016/j.celrep.2014.09.028. Epub 2014 Oct 23.

7.

Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program.

Keir ST, Maris JM, Reynolds CP, Kang MH, Kolb EA, Gorlick R, Lock R, Carol H, Morton CL, Wu J, Kurmasheva RT, Houghton PJ, Smith MA.

Pediatr Blood Cancer. 2013 May;60(5):783-90. doi: 10.1002/pbc.24368. Epub 2013 Jan 17.

8.

Mitogen-activated protein kinase (MEK/ERK) inhibition sensitizes cancer cells to centromere-associated protein E inhibition.

Mayes PA, Degenhardt YY, Wood A, Toporovskya Y, Diskin SJ, Haglund E, Moy C, Wooster R, Maris JM.

Int J Cancer. 2013 Feb 1;132(3):E149-57. doi: 10.1002/ijc.27781. Epub 2012 Sep 28.

9.

Treatment of a solid tumor using engineered drug-resistant immunocompetent cells and cytotoxic chemotherapy.

Dasgupta A, Shields JE, Spencer HT.

Hum Gene Ther. 2012 Jul;23(7):711-21. doi: 10.1089/hum.2011.172. Epub 2012 Apr 18.

10.

A single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma.

Furman WL, McGregor LM, McCarville MB, Onciu M, Davidoff AM, Kovach S, Hawkins D, McPherson V, Houghton PJ, Billups CA, Wu J, Stewart CF, Santana VM.

Invest New Drugs. 2012 Aug;30(4):1660-70. doi: 10.1007/s10637-011-9724-3. Epub 2011 Jul 28.

11.

Pharmacologic management of high-risk neuroblastoma in children.

Ganeshan VR, Schor NF.

Paediatr Drugs. 2011 Aug 1;13(4):245-55. doi: 10.2165/11591630-000000000-00000. Review.

12.

Camptothecin-based regimens for treatment of ewing sarcoma: past studies and future directions.

Wagner L.

Sarcoma. 2011;2011:957957. doi: 10.1155/2011/957957. Epub 2011 Apr 6.

13.

Dose escalation of intravenous irinotecan using oral cefpodoxime: a phase I study in pediatric patients with refractory solid tumors.

McGregor LM, Stewart CF, Crews KR, Tagen M, Wozniak A, Wu J, McCarville MB, Navid F, Santana VM, Houghton PJ, Furman WL, Rodriguez-Galindo C.

Pediatr Blood Cancer. 2012 Mar;58(3):372-9. doi: 10.1002/pbc.23075. Epub 2011 Apr 20.

14.

Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children's Oncology Group study.

Bagatell R, London WB, Wagner LM, Voss SD, Stewart CF, Maris JM, Kretschmar C, Cohn SL.

J Clin Oncol. 2011 Jan 10;29(2):208-13. doi: 10.1200/JCO.2010.31.7107. Epub 2010 Nov 29.

15.

Activity of irinotecan and temozolomide in the presence of O6-methylguanine-DNA methyltransferase inhibition in neuroblastoma pre-clinical models.

Cai W, Maldonado NV, Cui W, Harutyunyan N, Ji L, Sposto R, Reynolds CP, Keshelava N.

Br J Cancer. 2010 Oct 26;103(9):1369-79. doi: 10.1038/sj.bjc.6605927. Epub 2010 Oct 5.

16.

Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium study.

Wagner LM, Perentesis JP, Reid JM, Ames MM, Safgren SL, Nelson MD Jr, Ingle AM, Blaney SM, Adamson PC.

Pediatr Blood Cancer. 2010 Apr;54(4):538-45. doi: 10.1002/pbc.22407.

Supplemental Content

Support Center